Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.32 |
| ▸ | TYK2 | P29597 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1076235 | 0.94 | ALK (0.39) | JAK2PIK3CDPIK3CAALKJAK1 | |
| SCHEMBL1074236 | 0.94 | ALK (0.39) | JAK2PIK3CDPIK3CAALKJAK1 | |
| Trifluoroacetic Acid SCHEMBL4352218 | 0.90 | ALK (0.37) | JAK2ALKJAK1TYK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL4355877 | 0.90 | ALK (0.37) | JAK2ALKJAK1TYK2JAK3 | |
| SCHEMBL4359105 | 0.90 | ALK (0.40) | JAK2PIK3CDPIK3CAALKJAK1 | |
| SCHEMBL13634073 | 0.89 | JAK2 (0.34) | JAK2PIK3CDALKJAK1TYK2 | |
| SCHEMBL13632945 | 0.89 | NAMPT (0.35) | JAK2PIK3CDALKJAK1TYK2 | |
| SCHEMBL13633107 | 0.89 | ALK (0.36) | JAK2ALKJAK1TYK2JAK3 | |
| SCHEMBL13633015 | 0.87 | ALK (0.36) | JAK2ALKJAK1TYK2JAK3 | |
| Trifluoroacetic Acid SCHEMBL4356867 | 0.86 | ALK (0.37) | JAK2ALKJAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | JAK2 1/4885PIK3CD 56/4885PIK3CA 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.